Status:
RECRUITING
Better Risk Perception Via Patient Similarity to Control Hyperglycemia and Sustained by Telemonitoring
Lead Sponsor:
SingHealth Polyclinics
Collaborating Sponsors:
AISG Health Grand Challenge
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
36-65 years
Phase:
NA
Brief Summary
Background: Diabetes significantly raises the likelihood of complications, thereby increasing the risk of diabetes-related mortality, particularly due to vascular complications. It is vital to address...
Detailed Description
Diabetes has emerged as a significant public health concern globally, and Singapore is no exception. As of 2022, 8.5% of the adults in Singapore is affected by diabetes and the number is expected to r...
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus on follow-up at the study site for at least 12 months
- Age 36 to 65 years
- At least one HbA1c reading ≥ 8.0% within the last 6 months
- Able to read and speak English
Exclusion
- Not a Singapore citizen or permanent resident
- Pregnant
- End-stage kidney disease or on renal replacement therapy
- Known terminal illness
- Visual and/or hearing impairment
- Cognitive impairment or mental illness
- Unable to provide informed consent
Key Trial Info
Start Date :
July 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT06607497
Start Date
July 15 2024
End Date
September 30 2025
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SingHealth Polyclinics
Singapore, Singapore, Singapore